向PAK4通过调节ER应激应变来逆转NSCLC中的西斯普拉丁耐药性
Shixin Liu1,2, Pingshan Yang1, Lu Wang2
1Department of Thoracic Surgery, the First Affiliated Hospital of Jinan University, No.601 Huangpu Road West, Guangzhou, Guangdong, 510632, China.
Cell death discovery
|January 18, 2024
概括
这项研究表明,P21激活激酶4 (PAK4) 驱动非小细胞肺癌 (NSCLC) 的化学抵抗. 抑制PAK4通过调节内细胞网膜应激和MEK1-GRP78通路来增强对西斯的敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 耐化学反应是治疗非小细胞肺癌 (NSCLC) 的一个主要挑战.
- P21激活酶4 (PAK4) 与NSCLC的进展有关,但其在西斯普拉丁耐药性中的作用尚不清楚.
研究的目的:
- 调查PAK4在NSCLC中对西斯普拉丁耐药性的作用.
- 探索PAK4作为克服化疗抵抗的潜在治疗点.
主要方法:
- 检查了PAK4表达在抗西斯普拉丁NSCLC瘤和细胞系中的表达.
- 评估了PAK4沉默对化学敏感性的影响.
- 研究了PAK4抑制对内质网膜应激和MEK1-GRP78通路的影响.
主要成果:
- 在耐性NSCLC中,PAK4表达升高.
- 沉默PAK4显著增加了对西斯的敏感性.
- 抑制PAK4通过调节内质网膜应激来使耐药细胞敏感.
- 抑制MEK1-GRP78通路在PAK4敲击后引起的敏感性.
结论:
- 在NSCLC中,PAK4对青抗性起着至关重要的作用.
- 向PAK4提供了一种潜在的策略,以提高NSCLC治疗疗效.
- 调节内质网膜应激和MEK1-GRP78通路是关键机制.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K